Global Information
회사소개 | 문의

중국의 글리메피리드(Glimepiride) 시장(2018-2022년)

Investigation Report on China´s Glimepiride Market, 2018-2022

리서치사 China Research and Intelligence
발행일 2018년 11월 상품 코드 334099
페이지 정보 영문 30 Pages
가격
US $ 2,200 ₩ 2,506,600 Unprintable PDF (Single User License)
US $ 3,300 ₩ 3,760,000 Printable & Editable PDF (Enterprisewide License)


중국의 글리메피리드(Glimepiride) 시장(2018-2022년) Investigation Report on China´s Glimepiride Market, 2018-2022
발행일 : 2018년 11월 페이지 정보 : 영문 30 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

중국의 글리메피리드(Glimepiride) 시장에 대해 조사했으며, 글리메피리드의 효능과 효과, 중국 시장의 특허 및 승인 현황, 매출 및 판매량 추이와 예측, 가격 동향, 주요 제조업체와 시장 점유율, 경쟁 환경과 전망, 주요 제조업체 개요 등을 정리하여 전해드립니다.

제1장 글리메피리드 관련 개념

  • 적응
  • 세계 시장의 판매 현황

제2장 중국의 글리메피리드 시장 개요

  • 특허 현황
  • 주요 제조업체
  • 시장 규모

제3장 중국의 글리메피리드 판매 현황 분석

  • 매출액
    • 총매출액
    • 지역별 매출액
  • 판매량
    • 총판매량
    • 지역별 판매량

제4장 중국의 글리메피리드 시장 : 주요 제조업체의 시장 점유율 조사

  • 매출액 기준 시장 점유율
  • 판매량 기준 시장 점유율

제5장 중국의 글리메피리드 시장 : 제형별 분석

  • 제형별 시장 점유율 : 매출액 기준
  • 제형별 시장 점유율 : 판매량 기준

제6장 중국 병원에서의 글리메피리드 기준가격

  • Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd(Trade Name : Amaryl)
  • Aventis(Italy)
  • Wanbang Biopharmaceuticals
  • Zhongnuo Pharma
  • Tianan Pharmaceutical
  • Guangzhou Hairui Pharmaceutical Co., Ltd
  • Sichuan Pudu Pharmaceutical Plant

제7장 중국 시장의 글리메피리드 주요 제조업체

  • Hangzhou Sanofi-Synthelabo Minsheng Pharmaceutical Co., Ltd
  • Aventis(Italy)
  • Wanbang Biopharmaceuticals
  • Zhongnuo Pharma
  • Tianan Pharmaceutical
  • Guangzhou Hairui Pharmaceutical Co., Ltd

제8장 중국의 글리메피리드 시장 전망

  • 시장 규모 예측
  • 경쟁 구도 예측
LSH 15.07.14

Description

Glimepiride is a third-generation sulfonylurea insulin secretagogue. Sanofi's brand-name drug (trade name: Amaryl) have been marketed in many countries after it was approved by the FDA (U.S. Food and Drug Administration) on Nov. 30, 1995. Glimepiride is the sulfonylurea hypoglycemic agent that has best clinical effectiveness as well as the first sulfonylurea approved by the FDA to be used together with insulin. It does much better in sensitizing and simulating insulin than other sulfonylureas. For type 2 diabetic patients with insulin resistance (reduced glucose utilization in peripheral tissues), Glimepiride reduces blood glucose by sensitizing and simulating insulin. For type 2 diabetic patients with insulin secretion dysfunction, Glimepiride reduces blood glucose by stimulating insulin secretion.

According to CRI, with the development of China's economy, the rise of urbanization level, and the aging of population, the life style of Chinese people is changing, which increases the obese population and the incidence of diabetes in China. It is estimated that the number of type 2 diabetic patients in China had surpassed 1 million by the end of 2017, and is growing by 1.5 million to 2 million every year. The growing number of diabetics in China promotes the growth of the antidiabetic drug market.

According to CRI, generic products have sprung up one after another since 2004 when Sanofi (Beijing) Pharmaceutical Co., Ltd. launched Amaryl in China. In 2017, the market size of Glimepiride in China was about CNY 302 million. There are over 10 Glimepiride manufacturers in China. The major market players include Sanofi (Beijing) Pharmaceutical Co., Ltd., Jiangsu Wanbang Biopharmaceuticals Co., Ltd., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., and Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. By sales value, in 2017, Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Amaryl captured more than 80% share of China's Glimepiride market.

It is expected that as the number of diabetics continues to grow, China's Glimepiride market will have huge growth potential in the next few years.

Topics Covered:

  • Situation of diabetes in China
  • Sales of Glimepiride in China
  • Competition on China's Glimepiride market
  • Prices of Glimepiride in China
  • Forecasts on China's Glimepiride market from 2018 to 2022

Table of Contents

Table of Contents

1 Relevant Concepts of Glimepiride

  • 1.1 Indications for Glimepiride
  • 1.2 Development of Glimepiride in China
  • 1.3 Governmental Approval of Glimepiride in China

2 Sales of Glimepiride in China, 2013-2017

  • 2.1 Sales Value of Glimepiride
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Glimepiride
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Glimepiride by Dosage Form in China, 2013-2017
    • 2.3.1 Tablets
    • 2.3.2 Capsules
    • 2.3.3 Pills

3 Analysis on Major Glimepiride Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Glimepiride Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Sanofi (Beijing) Pharmaceutical Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride in China
  • 3.3 Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride in China
  • 3.4 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
  • 3.5 Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.
  • 3.6 Sanofi

4 Prices of Glimepiride in China, 2017-2018

  • 4.1 Sanofi (Beijing) Pharmaceutical Co., Ltd. (Amaryl)
  • 4.2 Jiangsu Wanbang Biopharmaceuticals Co., Ltd. (Wansuping)
  • 4.3 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (Linmeixin)
  • 4.4 Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. (Yousu)
  • 4.5 Sanofi (Amaryl)

5 Prospect of China's Glimepiride Market, 2018-2022

  • 5.1 Forecast on Market Size
  • 5.2 Forecast on Market Trend

Selected Charts

  • Chart Sales of Glimepiride in China, 2013-2017
  • Chart Sales Value of Glimepiride in Parts of China, 2013-2017
  • Chart Sales Volume of Glimepiride in China, 2013-2017
  • Chart Sales Volume of Glimepiride in Parts of China, 2013-2017
  • Chart Sales Value of Glimepiride Tablets in China, 2013-2017
  • Chart Sales Volume of Glimepiride Tablets in China, 2013-2017
  • Chart Sales Value of Glimepiride Capsules in China, 2013-2017
  • Chart Sales Value of Glimepiride Pills in China, 2013-2017
  • Chart Sales Volume of Glimepiride Pills in China, 2013-2017
  • Chart Market Share of Top 5 Glimepiride Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Glimepiride Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Volume of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Value of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Value of CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s Glimepiride, 2013-2017
  • Chart Sales Value of Sanofi's Glimepiride, 2013-2017
  • Chart Prices of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
  • Chart Prices of Sanofi's Glimepiride in Parts of China, 2017-2018
Back to Top
전화 문의
이용안내
 
BCC Research